Airway epithelial-targeted nanoparticles for asthma therapy

Abstract

Asthma is a common chronic inflammatory disease associated with intermittent airflow obstruction caused by airway inflammation, mucus overproduction, and bronchial hyperresponsiveness. Despite current treatment and management options, a large number of patients with asthma still have poorly controlled disease and are susceptible to acute exacerbations, usually caused by a respiratory virus infection. As a result, there remains a need for novel therapies to achieve better control and prevent/treat exacerbations. Nanoparticles (NPs), including extracellular vesicles (EV) and their synthetic counterparts, have been developed for drug delivery in respiratory diseases. In the case of asthma, where airway epithelium dysfunction, including dysregulated differentiation of epithelial cells, impaired barrier, and immune response, is a driver of disease, targeting airway epithelial cells with NPs may offer opportunities to repair or reverse these dysfunctions with therapeutic interventions. EVs possess multiple advantages for airway epithelial targeting, such as their natural intrinsic cell-targeting properties and low immunogenicity. Synthetic NPs can be coated with muco-inert polymers to overcome biological barriers such as mucus and the phagocytic response of immune cells. Targeting ligands could be also added to enhance targeting specificity to epithelial cells. The review presents current understanding and advances in NP-mediated drug delivery to airway epithelium for asthma therapy. Future perspectives in this therapeutic strategy will also be discussed, including the development of novel formulations and physiologically relevant preclinical models.

Nanomedicine strategies to target coronavirus

“…Clearance of agents form the mucus can occur within 30 min, giving applied nanocarriers a limited time to overcome the barrier and being taken up by or pass the epithelial lining [ 175 ]. Nonetheless several mucus-penetrating NPs (MPPs) have been developed over the last years, as extensively discussed elsewhere [ 173 , 175 , 176 ]. A general inspiration for the design of such MPPs are viruses, such as CoVs, that are able to penetrate the mucus with similar diffusion rates compared diffusion in water.…”

Galectin‐7 overexpression destroys airway epithelial barrier in transgenic mice

“…2014; Kan et al . 2020), Chronic obstructive pulmonary disease (COPD) (Khan et al . 2008; Shaykhiev et al .…”

Lung Inflammatory Response to Environmental Dust Exposure in Mice Suggests a Link to Regional Respiratory Disease Risk

“…Furthermore, repetitively exposed animals exhibited evidence of perivascular inflammation, while both acutely and repetitively SSDE-exposed mice had evidence of lung granulocyte influx ( Figure 2D – G ). Because angiogenesis, endothelial dysfunction, and changes in vascular density constitute distinct aspects of remodeled airways in respiratory diseases, 28 we next assessed the effects of the observed increased inflammatory cytokine secretion and immune cell influx on the lymphatic vasculature of the lung. Here, we stained lung sections with anti-LYVE-1 (lymphatic vessel hyaluronan receptor) antibody.…”